Skip to main content

Poolbeg Pharma upbeat on preliminary influenza drug results

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-upbeat-on-preliminary-influenza-drug-results-758545326

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  255.54
+0.58 (0.23%)
AAPL  331.39
+3.89 (1.19%)
AMD  500.74
-28.40 (-5.37%)
BAC  61.53
-0.06 (-0.10%)
GOOG  371.08
+0.87 (0.24%)
META  670.37
-10.94 (-1.61%)
MSFT  401.53
+5.90 (1.49%)
NVDA  207.57
-4.93 (-2.32%)
ORCL  126.47
-6.02 (-4.54%)
TSLA  389.30
-5.16 (-1.31%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.